Discover why VKTX's deep selloff offers a compelling opportunity with improved safety margins, promising GLP-1 candidates, ...

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $23.94, representing a +1.44% change from its previous close.

Here are the latest rating upgrades from Seeking Alpha analysts: Advanced Micro Devices (NASDAQ:AMD). Hold to buy by Kenio ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

Shares of Viking Therapeutics (VKTX) are moving lower in pre-market trading after Eli Lilly (LLY) announced topline Phase 3 results from ...

No one ever claimed investing in the biotech industry was a smooth ride, but for shareholders of Viking Therapeutics (NASDAQ: VKTX), the turbulence has been extremely challenging thus far. The stock ...

We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look ...

VKTX is still down 39.3% in 2025, hitting a more than 12-month bottom of $18.92 on April 9. Today's breakout has the shares ...

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid ...

Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to ...

Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. Viking doesn't sell weight loss drugs yet, but it could be on the way. The biotech is studying ...